Food and Drug Administration Advisory Panel Voted 12 to 1 to Recommend Approval of ORKAMBIâ¢ (lumacaftor/ivacaftor) to Treat People with Cystic Fibrosis Ages 12 and Older Who Have Two Copies of the F508del Mutation